REFERENCES

1. Platt FM. Emptying the stores: lysosomal diseases and therapeutic strategies. Nat Rev Drug Discov 2018;17:133-50.

2. Pandey MK, Burrow TA, Rani R, et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 2017;543:108-12.

3. Wraith JE. Lysosomal disorders. Semin Neonatol 2002;7:75-83.

4. Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev 2017;118:109-34.

5. Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr 2018;44:120.

6. Turner CT, Hopwood JJ, Brooks DA. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats. Mol Genet Metab 2000;69:277-85.

7. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40.

8. Hsu TR, Niu DM. Fabry disease: Review and experience during newborn screening. Trends Cardiovasc Med 2018;28:274-81.

9. Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis 2013;8:29.

10. Germain DP, Elliott PM, Falissard B, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep 2019;19:100454.

11. Kishnani PS, Dickson PI, Muldowney L, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab 2016;117:66-83.

12. Le SQ, Kan SH, Clarke D et al. A humoral immune response alters the distribution of enzyme replacement therapy in murine mucopolysaccharidosis type I. Mol Ther Methods Clin Dev 2018;8:42-51.

13. Neuwelt E, Abbott NJ, Abrey L, et al. Strategies to advance translational research into brain barriers. Lancet Neurol 2008;7:84-96.

14. Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target 2010;18:157-67.

15. Pardridge WM. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. Adv Drug Deliv Rev 2022;184:114234.

16. Zhu Y, Li X, Schuchman EH, Desnick RJ, Cheng SH. Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages. J Pharmacol Exp Ther 2004;308:705-11.

17. Safary A, Akbarzadeh Khiavi M, Mousavi R, Barar J, Rafi MA. Enzyme replacement therapies: what is the best option? Bioimpacts 2018;8:153-7.

18. Del Grosso A, Galliani M, Angella L, et al. Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease. Sci Adv 2019;5:eaax7462.

19. Santi M, Finamore F, Cecchettini A, et al. Protein delivery by peptide-based stealth liposomes: a biomolecular insight into enzyme replacement therapy. Mol Pharm 2020;17:4510-21.

20. Abasolo I, Seras-Franzoso J, Moltó-Abad M, et al. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1684.

21. Cabrera I, Abasolo I, Corchero JL, et al. α-Galactosidase-a loaded-nanoliposomes with enhanced enzymatic activity and intracellular penetration. Adv Healthc Mater 2016;5:829-40.

22. Ansari NH, He Q, Cook JD, Wen J, Srivastava SK. Delivery of liposome-sequestered hydrophobic proteins to lysosomes of normal and batten disease cells. J Neurosci Res 1997;47:341-7.

23. Choi H, Choi K, Choi C. Exosome-mediated delivery of active glucocerebrosidase to Gaucher model cells. Molecular Genetics and Metabolism 2019;126:S38-9.

24. Do MA, Levy D, Brown A, Marriott G, Lu B. Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles. Sci Rep 2019;9:17274.

25. Hugel B, Martínez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005;20:22-7.

26. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006;20:1487-95.

27. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010;78:838-48.

28. Matsumoto J, Stewart T, Banks WA, Zhang J. The transport mechanism of extracellular vesicles at the blood-brain barrier. Curr Pharm Des 2017;23:6206-14.

29. Saint-Pol J, Gosselet F, Duban-Deweer S, Pottiez G, Karamanos Y. Targeting and crossing the blood-brain barrier with extracellular vesicles. Cells 2020;9:851.

30. Seras-Franzoso J, Díaz-Riascos ZV, Corchero JL, et al. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders. J Extracell Vesicles 2021;10:e12058.

31. Haney MJ, Klyachko NL, Harrison EB, Zhao Y, Kabanov AV, Batrakova EV. TPP1 Delivery To Lysosomes With Extracellular Vesicles And Their Enhanced Brain Distribution In The Animal Model Of Batten Disease. Adv Healthc Mater 2019;8:e1801271.

32. Haney MJ, Zhao Y, Jin YS, Batrakova EV. Extracellular vesicles as drug carriers for enzyme replacement therapy to treat CLN₂ batten disease: optimization of drug administration routes. Cells 2020;9:1273.

33. European Medicines Agency, Sciences Medicines. Health.Brineura cedipose alpha.

34. Schulz A, Ajayi T, Specchio N, et al. CLN2 Study Group. Study of intraventricular cerliponase Alfa for CLN₂ Disease. N Engl J Med 2018;378:1898-907.